Current Report Filing (8-k)
June 12 2017 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
June
7, 2017
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.
|
37
North Orange Ave, Suite 607, Orlando, FL
|
|
32801
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD Disclosure
On
June 7, 2017, management of Immune Therapeutics, Inc., a Florida corporation (the “Company”) gave a presentation
related to the business and performance of the Company at LD Micro 7th Annual LD Micro Invitational Conference at the Luxe
Sunset Bel Air in Los Angeles.
Copies
of the presentation slides presented at the conference are attached hereto as Exhibit 99.1. The information contained herein and
the exhibit attached hereto shall be deemed furnished and not filed. The information contained in the presentation slides has
been provided for information purposes only and should not be construed as an offer to sell or a solicitation of an offer to purchase
any of the Company’s securities.
Section
9 – Financial Statements and Exhibits
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits. The following exhibits are filed herewith.
Exhibit
No.
|
|
Description
|
99.1
|
|
Power
Point Presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
Date:
June 9, 2017
|
By:
|
/s/
Noreen Griffin
|
|
|
Noreen
Griffin, CEO
|